Meropenem/vaborbactam activity : a new option for carbapenemase (KPC)-producing treatment.

Infections by carbapenemase (KPC)-producing represent a major challenge because of limited treatment strategies. New β-lactam/β-lactamase inhibitor associations may help to deal with this challenge. The aim of this study is to evaluate the susceptibility of KPC-producing for meropenem/vaborbactam in comparison with ceftazidime/avibactam against. Twenty-eight strains isolated from blood cultures were evaluated. Testing for susceptibility to meropenem/vaborbactam and ceftazidime/avibactam was performed by E-test gradient strip. All the clinical isolates were susceptible to meropenem/vaborbactam, while one strain was resistant to ceftazidime/avibactam with a MIC of 32 μg/ml. The median MIC of ceftazidime/avibactam evaluated after standardization was higher compared with that of meropenem/vaborbactam. Meropenem/vaborbactam could be an important turning point in the treatment of KPC-producing infections, especially considering the emergence of ceftazidime/avibactam resistance.